Multivalent Constitutive Agonists
Multiple classes of cell surface receptors require clustering for activation and to induce downstream intracellular signaling. These receptors are inherently difficult targets for conventional bivalent therapeutic antibodies, which are structurally limited to interaction with two receptors per molecule. In preclinical studies, we and others have observed that increasing the target binding valency of therapeutics targeting these classes of receptors can enhance clustering and achieve robust pathway agonism. We believe that multivalent therapeutic candidates built with our sdAb platform will more effectively target these hard-to-manipulate receptors, increasing the potential to achieve clinical benefit. We have developed higher order, multivalent antibodies that target TNFRSF members that contain four (tetravalent; INBRX-109, INBRX-110) or six (hexavalent; INBRX-106) antigen binding domains.
Conditional Immune Activators
Through protein engineering, Inhibrx has developed innovative therapeutic formats to create conditional immune activation selectively in the suppressive tumor micro-environment. Inhibrx has applied its single domain antibody (sdAb) platform to expand the therapeutic window beyond that of conventional therapeutics against highly promising targets, where limited efficacy was observed due to the concurrent induction of systemic toxicities. These therapeutics include a conditional 41BB agonist (INBRX-105), tumor targeted cytokine therapy and CD3 engaging bispecific antibodies.
Unique Protein Engineering
The first two therapeutics in the Inhibrx pipeline demonstrate our ability to create differentiated therapeutics using conventional antibody and fusion protein technologies. Inhibrx was the first to discover and develop an anti-CD47 antibody capable of blocking the SIRPα interaction without causing hemagglutination (INBRX-103) and the first to create a recombinant Alpha-1 Antitrypsin fusion protein that maintains the ability to inhibit its target protease, neutrophil elastase (INBRX-101). We continue to innovate in this space, and have also developed a recombinant, human asparaginase enzyme with extended serum half-life and a potentially reduced immunogenicity profile for the treatment of pediatric and adult acute lymphoblastic leukemia (INBRX-117).
There is urgent need for new therapeutics to address the epidemic of antibiotic resistance. Inhibrx is committed to addressing this global health threat with multiple ongoing efforts to address priority list pathogens. Our single domain antibody (sdAb) platform enables the creation of multivalent and multispecific antibodies that achieve the coordinated delivery of multiple therapeutic functions in a single molecule for optimal treatment of drug-resistant bacteria.